Hong Kong
· Delayed Price · Currency is HKD Sino Biopharmaceutical Statistics
Total Valuation
Sino Biopharmaceutical has a market cap or net worth of HKD 51.28 billion. The enterprise value is 57.48 billion.
| Market Cap | 51.28B |
| Enterprise Value | 57.48B |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | Sep 10, 2024 |
Share Statistics
Sino Biopharmaceutical has 18.18 billion shares outstanding. The number of shares has decreased by -2.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.18B |
| Shares Change (YoY) | -2.25% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 49.75% |
| Owned by Institutions (%) | 17.80% |
| Float | 9.14B |
Valuation Ratios
The trailing PE ratio is 22.61 and the forward PE ratio is 15.37. Sino Biopharmaceutical's PEG ratio is 1.07.
| PE Ratio | 22.61 |
| Forward PE | 15.37 |
| PS Ratio | 1.74 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | 8.30 |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.42, with an EV/FCF ratio of 9.30.
| EV / Earnings | 13.08 |
| EV / Sales | 1.93 |
| EV / EBITDA | 8.42 |
| EV / EBIT | 9.78 |
| EV / FCF | 9.30 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.15 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.43 |
| Debt / FCF | 1.68 |
| Interest Coverage | 16.51 |
Financial Efficiency
Return on equity (ROE) is 12.87% and return on invested capital (ROIC) is 7.35%.
| Return on Equity (ROE) | 12.87% |
| Return on Assets (ROA) | 5.54% |
| Return on Invested Capital (ROIC) | 7.35% |
| Return on Capital Employed (ROCE) | 13.12% |
| Revenue Per Employee | 1.22M |
| Profits Per Employee | 179,852 |
| Employee Count | 25,806 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.42% in the last 52 weeks. The beta is 0.68, so Sino Biopharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -2.42% |
| 50-Day Moving Average | 3.14 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 33.85 |
| Average Volume (20 Days) | 61,578,529 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of HKD 29.86 billion and earned 4.40 billion in profits. Earnings per share was 0.24.
| Revenue | 29.86B |
| Gross Profit | 24.24B |
| Operating Income | 6.31B |
| Pretax Income | 6.41B |
| Net Income | 4.40B |
| EBITDA | 7.20B |
| EBIT | 6.31B |
| Earnings Per Share (EPS) | 0.24 |
Balance Sheet
The company has 14.16 billion in cash and 10.40 billion in debt, giving a net cash position of 3.76 billion or 0.21 per share.
| Cash & Cash Equivalents | 14.16B |
| Total Debt | 10.40B |
| Net Cash | 3.76B |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 45.26B |
| Book Value Per Share | 1.94 |
| Working Capital | 3.52B |
Cash Flow
In the last 12 months, operating cash flow was 6.96 billion and capital expenditures -775.15 million, giving a free cash flow of 6.18 billion.
| Operating Cash Flow | 6.96B |
| Capital Expenditures | -775.15M |
| Free Cash Flow | 6.18B |
| FCF Per Share | 0.34 |
Margins
Gross margin is 81.16%, with operating and profit margins of 21.12% and 14.72%.
| Gross Margin | 81.16% |
| Operating Margin | 21.12% |
| Pretax Margin | 21.48% |
| Profit Margin | 14.72% |
| EBITDA Margin | 24.11% |
| EBIT Margin | 21.12% |
| FCF Margin | 20.70% |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 2.13%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 2.13% |
| Dividend Growth (YoY) | -25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 15.47% |
| Buyback Yield | 2.25% |
| Shareholder Yield | 4.38% |
| Earnings Yield | 8.57% |
| FCF Yield | 12.05% |
Stock Splits
The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.
| Last Split Date | Jul 20, 2020 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Sino Biopharmaceutical has an Altman Z-Score of 2.71. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.71 |
| Piotroski F-Score | n/a |